Quick answer: In 2023 the FDA placed 19 peptides on a restricted list that effectively stopped compounding pharmacies from preparing them. That began reversing in 2026. Twelve peptides came off the restricted list effective April 23, 2026, and the FDA’s Pharmacy Compounding Advisory Committee reviewed seven of them at its July 23–24, 2026 meeting. Coming off the restricted list is not FDA approval, and it is not the same as being cleared for compounding. Those are three different things, and the difference is the whole story.
Why your provider stopped offering peptides in 2023
If you were prescribed a peptide before 2023 and then told it was no longer available, you were not imagining a change in policy.
The FDA placed 19 widely used peptides on its Category 2 restricted list, which effectively ended licensed compounding pharmacies’ ability to prepare and dispense them. BPC-157, thymosin alpha-1, TB-500, CJC-1295, ipamorelin, AOD-9604, and more than a dozen others left legitimate clinical supply chains almost overnight.
Understanding what Category 2 means matters, because the term gets misused constantly. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, the FDA maintains categories determining which bulk drug substances compounding pharmacies may use. Category 1 covers substances eligible for compounding. Category 2 covers substances identified as presenting potential safety risks and not currently eligible for routine compounding. Category 3 covers substances with insufficient information for full evaluation.
Here is the part people get wrong. Category 2 designation does not equal FDA approval and it does not equal formal prohibition. It reflects regulatory concern about safety data, immunogenicity, aggregation risk, sterility, and insufficient clinical evidence.
Practically, though, the effect was the same as a ban. The FDA’s position was that Category 2 means do not compound, and compliant providers avoided prescribing compounds their pharmacy could not legally make.
What changed in 2026
The reversal started with a public conversation rather than a Federal Register notice, which is unusual. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said during a podcast appearance that roughly 14 of the 19 restricted peptides were expected to move from Category 2 back to Category 1, restoring the legal pathway for licensed compounding pharmacies to prepare them under physician prescription.
The formal action followed. In April 2026 the FDA removed 12 peptides from Category 2. The affected substances included BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-C, Semax, and TB-500.
Then came the review stage, which happened days before this article was written. At its July 23–24, 2026 meeting, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for 503A eligibility: BPC-157, KPV, TB-500, and MOTS-C on July 23, and Emideltide (also called DSIP), Semax, and Epitalon on July 24. Five additional peptides go to a later meeting before the end of February 2027.
Reporting on the reclassification indicates BPC-157, thymosin alpha-1, TB-500, CJC-1295, ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV, and MOTS-C are among those expected to return, while roughly five including melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF are expected to remain restricted over ongoing safety concerns.
One important procedural detail: the committee makes recommendations to the FDA rather than approving peptides itself. A favorable review is a step, not a finish line.
The three-part distinction that protects you
This is the section to screenshot before you spend money anywhere.
Coming off the Category 2 list, being reviewed for 503A eligibility, and FDA drug approval are three different things. None of these peptides has completed the clinical trial and approval process. They remain prescription therapeutics that should be physician-managed and pharmacy-sourced.
Removal from Category 2 does not mean unrestricted compounding approval. And on the specific compound everyone asks about: BPC-157 came off Category 2 effective April 23, 2026 and was under review in July 2026. It is not an FDA-approved drug and it is not a legal over-the-counter supplement.
So when a website tells you a peptide is “now FDA approved” or “legal again,” that is either sloppy writing or a deliberate misread. Both should cost them your business.
Worth separating out clearly: FDA-approved peptide drugs such as semaglutide are fully legal with a prescription. Compounded peptides are legal when prepared by licensed pharmacies under 503A or 503B regulations for patients with valid prescriptions. Research peptides can be legally purchased for legitimate research purposes. That third category is where most of the danger lives.
The gray market problem
Search any peptide name and you will find sites selling vials with a disclaimer reading “for research use only, not for human consumption.” Those products are not manufactured under pharmacy sterility standards, are not tested for identity or purity in any way you can verify, and the disclaimer exists specifically to transfer legal exposure to you.
What we see clinically from gray-market use:
- Injection site reactions and abscesses from non-sterile preparation
- Dosing that bears no relationship to the label because concentration was never verified
- Products containing something other than what was ordered
- No adverse event pathway, because there is no prescriber and no pharmacy
The reclassification news has made this worse, not better. Every headline about peptides “coming back” drives search volume, and gray-market sellers are the ones buying ads against it.
What legitimate peptide therapy involves
If a clinic in the Tampa Bay area offers peptide therapy, these are reasonable things to expect and reasonable questions to ask.
A prescriber evaluates you first. Peptides are prescription therapeutics. An intake form and a credit card is not an evaluation.
Baseline labs where relevant. Depending on the goal, that may include metabolic panel, lipids, hormone levels, inflammatory markers, or IGF-1.
A named pharmacy. Ask which 503A or 503B pharmacy fills the prescription and whether that pharmacy is currently able to prepare the specific compound. A clinic that cannot answer this is not sourcing carefully.
Honest framing of evidence. Most peptides under discussion have preclinical or early clinical data, not large randomized trials. BPC-157, for example, has been studied extensively in preclinical models for gut healing, musculoskeletal repair, and tendon recovery — preclinical meaning largely animal and laboratory work. That is a legitimate reason for interest and an insufficient basis for guarantees.
Monitoring and a stopping point. Follow-up labs, symptom tracking, and a defined reassessment date.
No pressure to prepay for long protocols. Given that regulatory status is actively shifting, committing to twelve months of a compound whose availability could change is not in your interest.
Where this leaves patients in Brandon right now
As of late July 2026, the picture is genuinely in motion. Twelve peptides are off the restricted list. Seven were just reviewed. Five more wait until early 2027. Pharmacy availability varies, and availability differs by state and by pharmacy even for the same compound.
Our position at Brandon Medical Center is straightforward. We will discuss what the current evidence supports, tell you plainly when something is early-stage or unavailable, and we will not sell you a protocol built on a regulatory status that might change next quarter. For several goals patients bring to us — fatigue, body composition, recovery, metabolic health — there are FDA-approved options with substantially stronger evidence behind them, and those are usually the right first conversation.
If peptide therapy turns out to be a reasonable fit for you, we will source it through a licensed pharmacy with a real prescription and real follow-up. If it is not a fit, we will say so.
Talk to someone who will give you the actual answer
The peptide conversation is full of confident claims from people with something to sell. If you want a clear-eyed assessment of whether peptide therapy fits your goals, and what the alternatives are, come talk to us.
Call Brandon Medical Center at (813) 502-6430 or request an appointment online. We are at 122 S Moon Ave, Brandon, FL 33511, serving Brandon, Valrico, Riverview, Seffner, and the surrounding Hillsborough County area.
Frequently asked questions
Is BPC-157 legal in 2026?
It came off the FDA’s Category 2 restricted list effective April 23, 2026 and was reviewed by the Pharmacy Compounding Advisory Committee in July 2026. It is not an FDA-approved drug and it is not a legal dietary supplement. Whether a pharmacy can currently compound it depends on the outcome of that review process and on the individual pharmacy.
What is the difference between Category 1 and Category 2?
Category 1 substances are eligible for use in pharmacy compounding. Category 2 substances have been identified as presenting potential safety risks and are not eligible for routine compounding.
Are peptides the same as GLP-1 weight loss medications?
Semaglutide and tirzepatide are peptide-based drugs, but they are FDA-approved with completed clinical trials, which puts them in an entirely different regulatory and evidence category than compounded peptides.
Can I buy peptides online without a prescription?
Products sold online labeled “research use only” are not intended for human use, are not prepared to pharmacy sterility standards, and carry real risk of contamination and incorrect dosing. We do not recommend it under any circumstances.
Does insurance cover peptide therapy?
Generally no. Compounded peptides are almost always out of pocket. FDA-approved medications may be covered depending on your plan and diagnosis.
Will more peptides become available later in 2026?
Five remaining peptides are scheduled for review before the end of February 2027. Status may change, so ask at your appointment rather than relying on an article date.
Regulatory status described here reflects publicly available information as of July 29, 2026 and is subject to change. This article is general information, not medical advice.
